Enlarge image
Curevac: The vaccine candidate missed the statistical targets in an intermediate examination.
The stock collapses
Photo: THOMAS KIENZLE / AFP
"In a previously unprecedented environment with at least 13 variants within the subset of study participants examined in this interim analysis, CVnCoV achieved a preliminary effectiveness of 47 percent against COVID-19 disease of any severity and thus did not meet the specified statistical success criteria." The CureVac share traded in the USA collapsed in after-hours trading by almost 40 percent.
Initial analyzes have shown that the effectiveness depends on the age group examined and the strain of the virus, it said.
The Data Safety Monitoring Board (DSMB) has confirmed a good safety profile and the study will continue until the final analysis.
The first-generation vaccine candidate is in the final stages of clinical development.
An initial interim analysis did not reveal any safety concerns.
CureVac works with Bayer.
la / reuters
